Magnetic resonance spectroscopy in cancer

New Techniques in Oncologic Imaging

Volumn , Issue , 2005, Pages 193-212

  Alger, Jeffry R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883979582     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (60)

1. Griffiths JR, Cady E, Edwards RH, McCready VR, Wilkie DR, Wiltshaw E. 31P-NMR studies of a human tumour in situ. Lancet 1983; 1(8339):1435-1436.
2. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992; 5(5):303-324.
3. Barker PB, Glickson JD, Bryan RN. In vivo magnetic resonance spectroscopy of human brain tumors. Top Magn Reson Imaging 1993; 5(1):32-45.
4. Tien RD, Lai PH, Smith JS, Lazeyras F. Single-voxel proton brain spectroscopy exam (PROBE/SV) in patients with primary brain tumors. AJR Am J Roentgenol 1996; 167(1):201-209.
5. Webb PG, Sailasuta N, Kohler SJ, Raidy T, Moats RA, Hurd RE. Automated singlevoxel proton MRS: technical development and multisite verification. Magn Reson Med 1994; 31(4):365-373.
6. Nelson SJ. Imaging of brain tumors after therapy. Neuroimaging Clin N Am 1999; 9(4):801-819.
7. Matthews PM, Wylezinska M, Cadoux-Hudson T. Novel approaches to imaging brain tumors. Hematol Oncol Clin North Am 2001; 15(4):609-630.
8. Leclerc X, Huisman TA, Sorensen AG. The potential of proton magnetic resonance spectroscopy [(1)H-MRS] in the diagnosis and management of patients with brain tumors. Curr Opin Oncol 2002; 14(3):292-298.
9. Burtscher IM, Holtas S. Proton magnetic resonance spectroscopy in brain tumours:clinical applications. Neuroradiology 2001; 43(5):345-352.
10. Ronen SM, Leach MO. Imaging biochemistry: applications to breast cancer. Breast Cancer Res 2001; 3(1):36-40.
11. Katz-Brull R, Lavin PT, Lenkinski RE. Clinical utility of proton magnetic resonance spectroscopy in characterizing breast lesions. J Natl Cancer Inst 2002; 94(16):1197-1203.
12. Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined magnetic resonance imaging and spectroscopic imaging approach to molecular imaging of prostate cancer. J Magn Reson Imaging 2002; 16(4):451-463.
13. Swanson MG, Vigneron DB, Tran TK, Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. Cancer Invest 2001; 19(5):510-523.
14. Fulham MJ, Bizzi A, Dietz MJ, et al. Mapping of brain tumor metabolites with proton MR spectroscopic imaging: clinical relevance. Radiology 1992; 185(3):675-686.
15. Herholz K, Heindel W, Luyten PR, et al. In vivo imaging of glucose consumption and lactate concentration in human gliomas. Ann Neurol 1992; 31(3):319-327.
16. Ricci PE, Pitt A, Keller PJ, Coons SW, Heiserman JE. Effect of voxel position on singlevoxel MR spectroscopy findings. AJNR Am J Neuroradiol 2000; 21(2):367-374.
17. Kurhanewicz J, Vigneron DB, Nelson SJ. Three-dimensional magnetic resonance spectroscopic imaging of brain and prostate cancer. Neoplasia 2000; 2(1-2):166-189.
18. Alger JR, Frank JA, Bizzi A, et al. Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET. Radiology 1990; 177(3):633-641.
19. Danielsen ER, Michaelis T, Ross BD. Three methods of calibration in quantitative proton MR spectroscopy. J Magn Reson B 1995; 106(3):287-291.
20. Gupta RK, Cloughesy TF, Sinha U, et al. Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 2000; 50(3):215-226.
21. Meyerand ME, Pipas JM, Mamourian A, Tosteson TD, Dunn JF. Classification of Biopsy-Confirmed Brain Tumors Using Single-Voxel MR Spectroscopy. AJNR Am J Neuroradiol 1999; 20(1):117-123.
22. Isobe T, Matsumura A, Anno I, et al. Quantification of cerebral metabolites in glioma patients with proton MR spectroscopy using T2 relaxation time correction. Magn Reson Imaging 2002; 20(4):343-349.
23. Gillies RJ, Barry JA, Ross BD. In vitro and in vivo 13C and 31P NMR analyses of phosphocholine metabolism in rat glioma cells. Magn Reson Med 1994; 32(3):310-318.
24. Aiken NR, Gillies RJ. Phosphomonoester metabolism as a function of cell proliferative status and exogenous precursors. Anticancer Res 1996; 16(3B):1393-1397.
25. Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether-phospholipid synthesis. Cancer Res 2002; 62(7):1966-1970.
26. Ackerstaff E, Pflug BR, Nelson JB, Bhujwalla ZM. Detection of increased choline compounds with proton nuclear magnetic resonance spectroscopy subsequent to malignant transformation of human prostatic epithelial cells. Cancer Res 2001; 61(9):3599-3603.
27. Sabatier J, Gilard V, Malet-Martino M, et al. Characterization of choline compounds with in vitro 1H magnetic resonance spectroscopy for the discrimination of primary brain tumors. Invest Radiol 1999; 34(3):230-235.
28. Tzika AA, Cheng LL, Goumnerova L, et al. Biochemical characterization of pediatric brain tumors by using in vivo and ex vivo magnetic resonance spectroscopy. J Neurosurg 2002; 96(6):1023-1031.
29. Cheng LL, Anthony DC, Comite AR, Black PM, Tzika AA, Gonzalez RG. Quantification of microheterogeneity in glioblastoma multiforme with ex vivo high-resolution magic-angle spinning (HRMAS) proton magnetic resonance spectroscopy. Neuro-oncol 2000; 2(2):87-95.
30. Nakagami K, Uchida T, Ohwada S, Koibuchi Y, Morishita Y. Increased Choline Kinase Activity in 1,2-Dimethylhydrazine-Induced Rat Colon Cancer. Jpn J Cancer Res 1999; 90(11):1212-1217.
31. Ramirez dM, Gutierrez R, Ramos MA, et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 2002; 21(27):4317-4322.
32. Ronen SM, Jackson LE, Beloueche M, Leach MO. Magnetic resonance detects changes in phosphocholine associated with ras activation and inhibition in NIH 3T3 Cells. Br J Cancer 2001; 84(5):691-696.
33. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999; 12(7):413-439.
34. Jensen JE, Drost DJ, Menon RS, Williamson PC. In vivo brain (31)P-MRS: measuring the phospholipid resonances at 4 Tesla from small voxels. NMR Biomed 2002; 15(5):338-347.
35. Murphy-Boesch J, Stoyanova R, Srinivasan R, et al. Proton-decoupled 31P chemical shift imaging of the human brain in normal volunteers. NMR Biomed 1993; 6(3):173-180.
36. Li CW, Kuesel AC, Padavic-Shaller KA, et al. Metabolic characterization of human soft tissue sarcomas in vivo and in vitro using proton-decoupled phosphorus magnetic resonance spectroscopy. Cancer Res 1996; 56(13):2964-2972.
37. Gillies RJ, Raghunand N, Karczmar GS, Bhujwalla ZM. MRI of the tumor microenvironment. J Magn Reson Imaging 2002; 16(4):430-450.
38. Birken DL, Oldendorf WH. N-acetyl-l-aspartic acid: a literature review of a compound prominent in 1H-NMR spectroscopic studies of brain. Neurosci Biobehav Rev 1989; 13(1):23-31.
39. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993; 13(3):981-989.
40. Cecil KM, Schnall MD, Siegelman ES, Lenkinski RE. The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat 2001; 68(1):45-54.
41. Kvistad KA, Bakken IJ, Gribbestad IS, et al. Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging 1999; 10(2):159-164.
42. Kurhanewicz J, Vigneron DB, Nelson SJ, et al. Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology 1995; 45(3):459-466.
43. Maintz D, Heindel W, Kugel H, Jaeger R, Lackner KJ. Phosphorus-31 MR spectroscopy of normal adult human brain and brain tumours. NMR Biomed 2002; 15(1):18-27.
44. Howe FA, Barton SJ, Cudlip SA, et al. Metabolic profiles of human brain tumors using quantitative in vivo 1H magnetic resonance spectroscopy. Magn Reson Med 2003; 49(2):223-232.
45. Negendank WG, Sauter R, Brown TR, et al. Proton magnetic resonance spectroscopy in patients with glial tumors: a multicenter study. J Neurosurg 1996; 84(3):449-458.
46. PreulMC, Caramanos Z, CollinsDL, et al. Accurate, noninvasive diagnosis of human brain tumors by using proton magnetic resonance spectroscopy. Nat Med 1996; 2(3):323-325.
47. Dowling C, Bollen AW, Noworolski SM, et al. Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. Am J Neuroradiol 2001; 22(4):604 [Comment In: AJNR Am J Neuroradiol. 2001 Apr;22(4):597-8 UI: 21185634].
48. Bruhn H, Frahm J, Gyngell ML, et al. Noninvasive differentiation of tumors with use of localized H-1 MR spectroscopy in vivo: initial experience in patients with cerebral tumors. Radiology 1989; 172(2):541-548.
49. Preul MC, Caramanos Z, Leblanc R, Villemure JG, Arnold DL. Using pattern analysis of in vivo proton MRSI data to improve the diagnosis and surgical management of patients with brain tumors. NMR Biomed 1998; 11(4-5):192-200.
50. Butzen J, Prost R, Chetty V, et al. Discrimination between neoplastic and nonneoplastic brain lesions by use of proton MR spectroscopy: the limits of accuracy with a logistic regression model. AJNR Am.J Neuroradiol 2000; 21(7):1213-1219.
51. Pirzkall A, McKnight TR, Graves EE, et al. MR-spectroscopy guided target delineation for high-grade gliomas. Int J Radiat Oncol Biol Phys 2001; 50(4):915-928.
52. Preul MC, Leblanc R, Caramanos Z, Kasrai R, Narayanan S, Arnold DL. Magnetic resonance spectroscopy guided brain tumor resection: differentiation between recurrent glioma and radiation change in two diagnostically difficult cases. Can J Neurol Sci 1998; 25(1):13-22.
53. Hall WA, Martin A, Liu H, Truwit CL. Improving diagnostic yield in brain biopsy:coupling spectroscopic targeting with real-time needle placement. J Magn Reson Imaging 2001; 13(1):12-15.
54. Vigneron D, Bollen A, McDermott M, et al. Three-dimensional magnetic resonance spectroscopic imaging of histologically confirmed brain tumors. Magn Reson Imaging 2001; 19(1):89-101.
55. Tedeschi G, Lundbom N, Raman R, et al. Increased choline signal coinciding with malignant degeneration of cerebral gliomas: a serial proton magnetic resonance spectroscopy imaging study. J Neurosurg 1997; 87(4):516-524.
56. Wald LL, Nelson SJ, Day MR, et al. Serial proton magnetic resonance spectroscopy imaging of glioblastoma multiforme after brachytherapy. J Neurosurg 1997; 87(4):525-534.
57. Graves EE, Nelson SJ, Vigneron DB, et al. A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas. Neurosurgery 2000; 46(2):319-326.
58. Graves EE, Nelson SJ, Vigneron DB, et al. Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurge. [Comment In: AJNR Am J Neuroradiol. 2001 Apr; 22(4):598-9 UI: 21185635]. AJNR Am J Neuroradiol 2001; 22(4):613-624.
59. Preul MC, Caramanos Z, Villemure JG, et al. Using proton magnetic resonance spectroscopic imaging to predict in vivo the response of recurrent malignant gliomas to tamoxifen chemotherapy. Neurosurgery 2000; 46(2)306-318.
60. Swanson MG, Vigneron DB, Tran TK, Kurhanewicz J. Magnetic resonance imaging and spectroscopic imaging of prostate cancer. Cancer Invest 1901; 19(5):510-523.